Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced participation in two upcoming investor conferences.
Details of each presentation are as follows:
H.C. Wainwright Gene Therapy and Gene Editing Conference
Fireside chat
Date: March 30, 2022
Time: 7:00 a.m. ET – available on demand
Chardan 6th Annual Genetic Medicines Manufacturing Summit
Fireside chat
Date: April 26, 2022
Time: 1:00 p.m. ET
Webcasts of the fireside chats will be available by visiting the Investors section of Tenaya’s website. A replay of each webcast will be available on the Tenaya website for approximately 30 days following each conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.
| Last Trade: | US$1.41 |
| Daily Change: | 0.02 1.44 |
| Daily Volume: | 3,320,931 |
| Market Cap: | US$234.780M |
November 10, 2025 August 06, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
